Kojic, Zvezdana Z., Ulrich Flö gel, Jü rgen Schrader, and Ulrich K. M. Decking. Endothelial NO formation does not control myocardial O2 consumption in mouse heart. Am J Physiol Heart Circ Physiol 285: H392-H397, 2003. First published February 27, 2003 10.1152/ajpheart.00836.2002To test whether endothelium-derived nitric oxide (NO) regulates mitochondrial respiration, NO was pharmacologically modulated in isolated mouse hearts, which were perfused at constant flow to sensitively detect small changes in myocardial O2 consumption (MV O2). Stimulation of NO formation by 10 M bradykinin (BK) increased coronary venous nitrite release fivefold to 58 Ϯ 33 nM (n ϭ 17). Vasodilatation by BK, adenosine (1 M), or papaverine (10 M) decreased perfusion pressure, left ventricular developed pressure (LVDP), and MV O2. In the presence of adenosine-induced vasodilatation, stimulation of endothelial NO synthesis by BK had no effect on LVDP and MV O2. Also, inhibition of NO formation by N G -monomethyl-L-arginine (L-NMMA, 100 M) did not significantly alter LVDP and MV O2. Similarly, intracoronary infusion of authentic NO Յ2 M did not influence LVDP or MV O2 (Ϫ1 Ϯ 1%). Only when NO was Ͼ2 M were contractile dysfunction and MV O2 reduction observed. Because BK-induced stimulation of endothelial NO formation and basal NO are not sufficient to impair MV O2 in the saline-perfused mouse heart, a tonic control of the respiratory chain by endothelial NO is difficult to conceive. nitrite; bradykinin; nitric oxide synthase inhibition NITRIC OXIDE (NO) is an important regulator of coronary vascular tone. It can also modulate myocardial energy metabolism and contractile function by a variety of mechanisms. Mitochondrial oxidative phosphorylation, e.g., at the level of cytochrome c oxidase, is very sensitive to blockade by NO (7). We demonstrated that arterially applied NO can induce contractile dysfunction by inhibiting O 2 consumption and ATP generation (10, 26) . NO has been reported to inhibit mitochondrial and cytosolic creatine kinase (18, 23) and may influence substrate utilization (5). Moreover, NO may influence contractility and energy demand by modulating ␤-adrenergic signal transduction (e.g., see Refs. 16, 43, 46) and via cGMP-dependent and -independent effects on Ca 2ϩ influx and cycling (3; for review, see Refs. 25, 29) .
To test whether endothelium-derived nitric oxide (NO) regulates mitochondrial respiration, NO was pharmacologically modulated in isolated mouse hearts, which were perfused at constant flow to sensitively detect small changes in myocardial O2 consumption (MV O2). Stimulation of NO formation by 10 M bradykinin (BK) increased coronary venous nitrite release fivefold to 58 Ϯ 33 nM (n ϭ 17). Vasodilatation by BK, adenosine (1 M), or papaverine (10 M) decreased perfusion pressure, left ventricular developed pressure (LVDP), and MV O2. In the presence of adenosine-induced vasodilatation, stimulation of endothelial NO synthesis by BK had no effect on LVDP and MV O2. Also, inhibition of NO formation by N G -monomethyl-L-arginine (L-NMMA, 100 M) did not significantly alter LVDP and MV O2. Similarly, intracoronary infusion of authentic NO Յ2 M did not influence LVDP or MV O2 (Ϫ1 Ϯ 1%). Only when NO was Ͼ2 M were contractile dysfunction and MV O2 reduction observed. Because BK-induced stimulation of endothelial NO formation and basal NO are not sufficient to impair MV O2 in the saline-perfused mouse heart, a tonic control of the respiratory chain by endothelial NO is difficult to conceive. nitrite; bradykinin; nitric oxide synthase inhibition NITRIC OXIDE (NO) is an important regulator of coronary vascular tone. It can also modulate myocardial energy metabolism and contractile function by a variety of mechanisms. Mitochondrial oxidative phosphorylation, e.g., at the level of cytochrome c oxidase, is very sensitive to blockade by NO (7) . We demonstrated that arterially applied NO can induce contractile dysfunction by inhibiting O 2 consumption and ATP generation (10, 26) . NO has been reported to inhibit mitochondrial and cytosolic creatine kinase (18, 23) and may influence substrate utilization (5) . Moreover, NO may influence contractility and energy demand by modulating ␤-adrenergic signal transduction (e.g., see Refs. 16, 43, 46) and via cGMP-dependent and -independent effects on Ca 2ϩ influx and cycling (3; for review, see Refs. 25, 29) .
In the heart, NO is formed predominantly in the coronary endothelium by the endothelial nitric oxide synthase (eNOS). NO is also formed within cardiomyocytes (2) , where ϳ20% of the eNOS protein resides (16) . The presence of NOS within or close to cardiac mitochondria was reported in several studies and attributed to eNOS in rats (4), inducible NOS (iNOS) in pigs (14) , and neuronal NOS (nNOS) in mouse heart (24) . Its physiological significance is under debate (14, 24) . Not only the formation of NO but also its metabolism is characterized by a high degree of compartmentalization. In the presence of O 2 , NO is oxidized to nitrite (NO 2 Ϫ ), e.g., in the intravascular space. The very fast reaction of NO with oxyhemoglobin to nitrate (NO 3 Ϫ ) and methemoglobin is considered to be a major route of NO catabolism. In addition, nitrosylation of hemoglobin and other proteins binds NO (17) . We have also recently shown that myoglobin contributes to intracellular NO degradation to nitrate (NO 3 Ϫ ) and is thus a potent intracellular scavenger of NO (13) .
The notion of a tonic control of myocardial oxygen consumption (MV O 2 ) by NO was supported by studies that demonstrated increased MV O 2 after blockade of NO synthesis in both isolated hearts and dogs in vivo (5, 9), whereas enhanced endothelial NO formation decreased MV O 2 , e.g., in myocardial tissue pieces (30, 44) . On the basis of these findings, it was concluded that endothelium-derived NO regulates cardiac MV O 2 (42) . However, increasing NO in the canine or reducing NO formation in the porcine or human heart had no effect on MV O 2 (8, 11, 41) . The recent recognition that myocardial myoglobin is a potent scavenger of NO (13) implies a steep intracellular NO-concentration gradient, which casts further doubt on the control of mitochondrial oxidative phosphorylation by endotheliumderived NO. We have therefore tested in well-oxygenated isolated mouse hearts whether enhancing endothelium-derived NO formation by bradykinin (BK) is quantitatively sufficient to decrease MV O 2 and contractile function. Myocardial NO levels were also modulated by application of authentic NO or inhibition of cardiac NO synthesis.
MATERIALS AND METHODS
General methods. A total of 97 hearts from C57/BL6 mice (body wt, 20-30 g) were isolated and perfused as described previously (13) . In brief, hearts with a wet weight of 116 Ϯ 11 mg were rapidly excised. The aorta was cannulated and the heart was perfused at a pressure of 100 mmHg in a nonrecirculating Langendorff mode with modified Krebs-Henseleit buffer [that contained (in mM) 116 NaCl, 4. A dedicated perfusion system (isolated heart size 1, HSE Harvard Apparatus; March-Hugstett, Germany) enabled temperature control of both inflow medium and ambient air. The following parameters were continuously recorded (Powerlab, ADInstruments; Castle Hill, NSW, Australia): coronary flow as measured by a transit-time ultrasonic flowmeter (HSE Harvard Apparatus), coronary perfusion pressure, left intraventricular pressure as assessed by a fluid-filled balloon, heart rate, and coronary venous PO 2. For reliable PO2 measurements, a fraction of the coronary venous effluent (0.5 ml/min) was sucked continuously through a small-diameter tube placed in the opening of the pulmonary artery across a Clark-type PO2 electrode (model 733, Diamond General; Ann Arbor, MI) by a peristaltic pump (Minipulse 3, Gilson Medical Electronics; Villiers-le-Bel, France). For the measurement of NO 2 Ϫ release, coronary venous effluent was collected as well.
Protocols. After completion of the preparation, hearts were initially perfused at constant pressure (100 mmHg, 13.3 kPa) inside a water-jacketed chamber set to 37°C. Cardiac pacing (500 min Ϫ1 ) was initiated and continued throughout. All hearts were allowed to equilibrate for 20 min before left ventricular end-diastolic pressure was set to 5 mmHg.
Twenty minutes after the onset of cardiac pacing, the coronary perfusion rate was fixed to the steady-state flow finally attained (in general, ϳ1.5-2.5 ml/min) and was maintained constant thereafter by a peristaltic pump. Basal functional parameters were acquired before subjecting the hearts to the different experimental protocols. In the first set of experiments, only BK was applied. In the presence of a constant flow, BK-induced vasodilatation resulted in a decrease in perfusion pressure and contractility. To verify that the latter effect was due to vasodilatation, the effects of two other vasodilators (adenosine and papaverine) were evaluated. In the main set of experiments, maximal vasodilatation was initiated by application of adenosine (1 M), which was continued throughout, before the different interventions under steady-state conditions were started. BK (10 M) , N Gmonomethyl-L-arginine (L-NMMA, 100 M), or authentic NO (33 nM-20 M) was applied in the presence of 1 M adenosine. For infusion of authentic NO, aqueous NO solutions were prepared as previously described in detail (26) . At the end of the experiment, hearts were gently blotted and weighed.
Measurement of MV O2. To enable the sensitive detection of even small changes in MV O2, hearts were perfused at a constant arterial PO2 (ϳ600 mmHg) and flow as previously described by others (19, 38) . In brief, measurement of the coronary venous PO2 (see General methods) allowed the determination of the arteriovenous PO2 difference. Because flow was maintained constant, any change in O2 consumption translated into a considerable change in coronary venous PO2. Preliminary experiments demonstrated both the stability of the PO2 electrode signal at a given PO2 (electrode drift, Ͻ0.1 mmHg/min) as well as the ability of the setup to respond to changes in MV O2: when the external Ca 2ϩ concentration was decreased from 2.5 to 2 mM, the coronary venous PO 2 increased by 16 Ϯ 2 mmHg, which corresponds to a change in MV O2 of 4% (n ϭ 3).
NO 2 Ϫ release measurements. To obtain a measure of cardiac NO formation, the NO 2 Ϫ release of the saline-perfused hearts was determined. Measurement of NO 3 Ϫ release was not attempted, because it is complicated by a low-NO 3 Ϫ content of the arterial inflow medium due to contamination of the commonly available medium constituents. The arterial inflow and coronary venous outflow NO 2 Ϫ concentrations were measured by a NO analyzer (NOA, model 280; Sievers; Boulder, CO) based on the chemiluminescence method. Comparison with NO 2 Ϫ standards enabled quantification with the detection limit being 1 pmol. To measure reliably the low coronary NO 2 Ϫ concentrations, an injection volume of 500 l was employed. For standards in the range of 1-200 nM NO 2 Ϫ , a linear correlation coefficient (r) of 0.98 was obtained.
Chemicals. BK, L-NMMA, and urethane were obtained from Sigma (Deisenhofen, Germany), and heparin was purchased from Hoffmann-LaRoche (Grenzau, Germany). All other reagents were obtained from Merck (Darmstadt, Germany). NO gas was obtained from AGA gas (Hamburg, Germany).
Data analysis. To compare control or basal values with those obtained during the different interventions, Student's t-test or one-way ANOVA followed by post hoc tests [leastsignificant difference (LSD) and Bonferroni as indicated] were employed as appropriate. A P value of Ͻ0.05 was considered to indicate a significant difference. All results are expressed as means Ϯ SD.
RESULTS
Isolated hearts of C57/BL6 mice were initially perfused at a pressure of 100 mmHg. The flow attained at the end of the equilibration period was fixed and maintained constant for the rest of the experiment. Therefore, any change in O 2 consumption resulted directly in a change in coronary venous PO 2 . Hearts were paced (500 min Ϫ1 ) and developed a left ventricular pressure (LVDP) of 81 Ϯ 18 mmHg at a myocardial perfusion of 16.8 Ϯ 3.4 ml ⅐ min Ϫ1 ⅐ g
Ϫ1
. This resulted in a coronary venous PO 2 of 119 Ϯ 44 mmHg, which translates into a MV O 2 of 10.
. In this model, coronary vasodilatation does not affect coronary flow (which is held constant) but results in a fall in coronary perfusion pressure. This is associated with a decrease in LVDP (the garden-hose phenomenon) and a decline in MV O 2 that is independent of the mechanism of action of the vasodilator: adenosineinduced maximal vasodilatation (1 M, n ϭ 17) caused a rapid decrease in LVDP (Ϫ34 Ϯ 9%) and an increase in coronary venous PO 2 by Ͼ30 mmHg due to a decrease in MV O 2 by 10.1 Ϯ 3.6% (see Fig. 1 ). Similarly, intracoronary infusion of BK (10 M, n ϭ 17) caused a drop in coronary perfusion pressure (Ϫ49%) that was associated with significant decreases in LVDP (Ϫ22%) and MV O 2 (Ϫ6%). Finally, papaverine (10 M, n ϭ 8) also decreased LVDP and MV O 2 to a comparable extent (Ϫ34 Ϯ 18% and Ϫ10.6 Ϯ 4.2%, respectively).
To eliminate this confounding factor, all further experiments were conducted in the presence of maximal vasodilatation (1 M adenosine). As can be seen in Fig.  1 , under these conditions, additional application of BK (n ϭ 12) had no further effect on coronary venous PO 2 (Ϫ6 Ϯ 6 mmHg compared to adenosine) and thus O 2 consumption. Neither did BK induce any additional changes in LVDP and coronary perfusion pressure.
To quantify the increase in NO formation induced by BK (10 M) in our experimental model, coronary venous NO 2 Ϫ release was determined. Basal coronary venous NO 2 Ϫ concentration was 22.8 Ϯ 12.6 nM (Fig. 2) . After correction for the arterial NO 2 Ϫ inflow (13 nM), basal myocardial NO 2 Ϫ release was calculated to be 192
, which translates into a coronary venous effluent concentration of 66 nM (Fig. 2) .
To test whether the basal formation of NO contributed to a tonic inhibition of MV O 2 , NO synthesis was blocked by L-NMMA (100 M) again in the presence of maximal vasodilatation (1 M adenosine). Under these conditions, L-NMMA induced small increases in coronary perfusion pressure (46.3 Ϯ 3.6 vs. 44.6 Ϯ 3.3 mmHg) and pressure development (43.8 Ϯ 5.0 vs. 41.5 Ϯ 3.8 mmHg) but had no effect on coronary venous PO 2 and thus O 2 consumption values, which were 10.97 Ϯ 2.15 mol ⅐ min Ϫ1 ⅐ g Ϫ1 before and 10.74 Ϯ 2.23 mol⅐min Ϫ1 ⅐g Ϫ1 after NOS blockade by L-NMMA (n ϭ 6).
To finally obtain insight into the NO concentration necessary to significantly inhibit mitochondrial oxidative phosphorylation and depress cardiac contractile function and MV O 2 , a concentration-response curve for exogenously applied authentic NO was obtained again in the presence of adenosine. As shown in Fig. 3 , in the concentration range Ͻ2 M, NO had no effect on either contractile function or MV O 2 (n ϭ 9). Only at concentrations Ͼ2 M did NO impair contractile function and decrease MV O 2 in a concentration-dependent manner (n ϭ 6).
DISCUSSION
This study clearly demonstrates that in the welloxygenated saline-perfused mouse heart, neither the basal levels of NO nor a fivefold rise in endothelial NO formation induced by BK influence MV O 2 . When modulating NO levels by arterial application of authentic NO, concentrations Ͼ2 M NO were required to induce a decrease in MV O 2 , which is a concentration three orders of magnitude higher than basal NO 2 Ϫ release. Thus endogenous endothelial NO formation does not regulate O 2 consumption in this model.
This conclusion is at variance with the postulate that endothelium-derived NO tonically controls MV O 2 (42) . This view was initially based on studies demonstrating (e.g., in dog hearts in vivo) an increase in MV O 2 upon blockade of NOS (39) . It was subsequently supported by studies in myocardial tissue pieces (wet weight, 40 mg), in which a reduction in MV O 2 on BK addition was consistently observed (30, 31, 45) . What could be the reason for this discrepancy?
Insufficient stimulation of NO formation by BK in the present study can be excluded: the BK concentration employed was 10-fold higher than the maximally effective vasodilatory concentration in mice (13) and was similar to that used in other studies (30) . Moreover, in the present study, the BK-induced increase in NO 2 Ϫ release (ϩ400%), which is a commonly used index of cardiac NO formation, by far exceeded that seen in guinea pig hearts (27) or canine coronary microvessels (33), the latter being sufficient to profoundly affect the MV O 2 of neighboring myocardial tissue pieces (33) . Moreover, the basal release of NO 2 Ϫ was similar to the NO 2 Ϫ and NO 3 Ϫ release measured in vivo (5). An important difference, however, may have been the degree of tissue oxygenation: the saline-perfused mouse heart as established in our laboratory was well oxygenated. This is indicated by a high creatine phosphate concentration and low P i and adenosine release, as well as its free energy of ATP hydrolysis (Ϫ63 kJ/mol; Refs. 12, 15). Its high rate of O 2 consumption (10 mol ⅐ min Ϫ1 ⅐ g Ϫ1 ) is in line with the high murine heart rate (500 min Ϫ1 in the present study). Although the coronary venous PO 2 in this model was significantly higher than values in vivo, already a moderate decrease in O 2 supply results in a substantial decrease in myocardial function and oxygenation (32) , which indicates near-physiological conditions. In contrast, when studying O 2 consumption in mouse myocardial tissue pieces, values of Ͻ0.2 mol ⅐ min Ϫ1 ⅐ g Ϫ1 were reported (30, 33) . This was possibly due to insufficient oxygenation at least in the tissue core, which would have rendered the pieces especially vulnerable to an increase in NO, because the inhibitory action of NO at cytochrome c oxidase is competitive with regard to O 2 (28) .
A BK-induced decrease in O 2 consumption due to enhanced eNO formation has not been seen in the heart in vivo to the best of our knowledge. The lack of effect of BK in the present study under well-controlled conditions despite a fivefold increase in endothelial NO formation therefore strongly suggests that endothelial NO does not regulate MV O 2 . One decisive factor for the observed dissociation of endothelial NO formation and mitochondrial oxidative phosphorylation is most likely the presence of high concentrations of the potent NO scavenger myoglobin (13) in cardiac tissue. This is a major player in the spatial confinement of NO formed by different isoforms (3) and constitutes a safeguard to protect mitochondria from endothelial NO. Myoglobinmediated NO inactivation not only diminishes the bioactivity of endothelium-derived NO in the control of mitochondrial respiration, it is most likely also this degradation pathway that made the application of very high arterial NO concentrations necessary to induce contractile dysfunction and a decline in MV O 2 in the present and previous studies (10, 26) . It cannot be excluded that extracellular degradation of NO, facilitated by the relatively high capillary PO 2 , results in a small decrease in the effectively applied NO concentration (see Ref. 26) . The intracellular myoglobin-mediated NO inactivation may also explain why high levels of myocardial iNOS overexpression increased NO 3 Ϫ release but had little effect on contractile function in a recent study (20) . In vivo, the intravascular degradation of NO by hemoglobin will even further reduce the myocardial effects of endothelium-derived NO.
In the present study, blockade of myocardial NO formation by L-NMMA did not increase MV O 2 . The concentration of L-NMMA employed (100 M) increased perfusion pressure (13) , decreased the deleterious effects of NO in reperfusion (12) , and increased O 2 consumption in the guinea pig heart (9) in previous studies of our group, excluding insufficient enzyme inhibition. In fact, much lower concentrations were employed by others in the field (35) . The lack of effect of L-NMMA was in line with previous studies in wildtype murine myocytes (24) and tissue pieces (30) . Also in humans and pigs, NOS blockade had no effect on MV O 2 (41) . In canine hearts, contradictory effects were reported (5, 8, 39, 40) , whereas in guinea pigs, inhibition of NO formation consistently increased MV O 2 (9) . The recent observation that enhanced expression of NOS in mitochondria [from dystrophin-deficient (mdx) mice] reduces cellular O 2 consumption (24) may shed some light on these potential species differences. We would like to suggest that the species-dependent level of mitochondrial NO formation governs the relative importance of NO in the control of mitochondrial respiration. In fact, the low activity of NOS in porcine mitochondria recently reported (14) is fully consistent with the lack of effect of NOS inhibition in pigs (11) , whereas the functionally active presence of NOS in guinea pig myocardial mitochondria (22) complements our previous observation of enhanced MV O 2 following NOS blockade in guinea pig hearts (9) .
The study of the role of NO in the regulation of MV O 2 is complicated by the fact that NO may influence energy demand and O 2 consumption not only on the level of the respiratory chain. NO modulates substrate uptake in vivo thereby resulting either in decreased glucose uptake and metabolism (36) or reduced fatty acid uptake (37) . Although this NO-mediated effect would either increase or decrease O 2 consumption, it does not play a role in the present study: glucose and pyruvate were the only substrates provided, and pyruvate will inhibit the mitochondrial metabolism of endogenous fatty acids. NO may modulate myocardial contractile efficiency by unknown mechanisms (21, 40) . Furthermore, NO may influence ␤-adrenergic signal transduction (1, 16, 46 ; see also 34, 43) , the directional effect being dependent on the extent of the adrenergic stimulation. This results in modulation of Ca 2ϩ entry via voltage-gated Ca 2ϩ channels and of Ca 2ϩ release from the sarcoplasmic reticulum. Whether NO exerts a positive or negative inotropic effect in vivo appears to be influenced also by the local NO concentration (29) , and the subcellular localization of NOS isoforms will play a significant role in this regard (3) . However, the physiological relevance of these effects is still under debate (6, 43) . The lack of a functional effect of increasing the endothelial production of NO or blocking NO formation in this study indicates a minor role of these regulatory pathways in the present model. It is thus well suited for studying the control of mitochondrial oxidative phosphorylation by endothelium-derived NO in the intact heart.
In the well-oxygenated saline-perfused murine heart, we found no evidence for the control of cardiac respiration by endothelium-derived NO. In view of the subcellular localization of different NOSs in the myocardium (e.g., see Ref.
3) and the potent inactivation of NO by myoglobin (13), a direct endothelial control of the mitochondrial oxidative phosphorylation of the myocytes appears to be highly unlikely. We propose that the sometimes contradictory effects of NOS inhibition on MV O 2 reported in the literature do not only reflect a variability of endothelial NO formation but may be also be due to differences in substrate selection and local NO formation, e.g., in the vicinity of sarcoplasmic reticula or caveolae or in mitochondria.
